Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial

Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-29T17:37:29.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH website updates and says that “Super Intelligence” is replacing “Artificial Intelligence” terminology across NIH content during the transition.
    Difference
    1%
    Check dated 2026-10-22T22:33:51.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The revision label in the footer changed from v3.7.1 to v3.7.2 on the access-denied page.
    Difference
    0.2%
    Check dated 2026-10-15T20:59:05.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The site footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-08T21:36:43.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the usual study record content and blocking access to the study details.
    Difference
    21%
    Check dated 2026-09-24T20:43:54.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.7.0 in place of the previous v3.6.6, indicating an updated version of the study documentation within the record. This reflects a metadata update on the study record rather than changes to the trial's substantive details.
    Difference
    0.0%
    Check dated 2026-09-17T21:54:12.000Z thumbnail image

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.